Article Text

Download PDFPDF
Immunomodulation and entry inhibition: selgantolimod’s double punch against hepatitis B virus

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors TB and MC wrote the manuscript. MU-Q designed the graphical abstract. All authors provided critical review of the manuscript.

  • Funding Funding provided by the European Union (ERC-AdG-2020-FIBCAN #101021417 (TB), HORIZON-HLTH-2021-DISEASE-04-07 D-SOLVE #101057917 (TB and MC)), the French government (ANR-10-IAHU-02, ANR-10-LABX-0028, ANR-21-RHUS-0001, TB), the German Center for Infection Research (DZIF; TTU‐05‐701, TTU‐05‐702, TTU-IICH-07-808, MC) and the Excellence Cluster RESIST (EXC2155, MC).

  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles